Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NeoImmuneTech receives FDA orphan drug designation for NT-I7 to treat Progressive Multifocal Leukoencephalopathy

pharmaceutical-business-reviewJune 17, 2020

Tag: NeoImmuneTech , NT-I7 , FDA , PML

PharmaSources Customer Service